| Greenwood Health And Living Community | |
| 937 Fry Rd, Greenwood, Indiana 46142 | |
| (317) 881-3535 | |
| Name | Greenwood Health And Living Community |
|---|---|
| Location | 937 Fry Rd, Greenwood, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 121 |
| Occupancy Rate | 60.25% |
| Medicare ID (CCN) | 155412 |
| Legal Business Name | Riverview Hospital |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1265422968 |
| Organization Name | RIVERVIEW HOSPITAL |
| Address | 937 Fry Rd, Greenwood, IN 46142 |
| Phone Number | 317-881-3535 |
News Archive
Improved care for patients undergoing cancer surgery is the focus of a pioneering worldwide study.
Cellectis, the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.
For patients with serious, ongoing hip pain, sometimes surgery is their best bet for relief. Given the choice between minimally invasive hip surgery and total hip replacement, most patients would choose the less invasive procedure, often done on an outpatient basis.
Prostate cancer is the second leading cause of cancer-related death among American men. Yet population-wide screening programs have not reduced the number of deaths from the disease. By focusing screening programs on the men who are at greatest risk for aggressive disease or diagnosis at a young age, researchers think they could improve mortality rates and personalize the screening approach.
Nabi Biopharmaceuticals announced today that it has successfully completed the technology transfer of program know-how associated with the sale of the PentaStaphTM vaccine candidate to GlaxoSmithKline Biologicals S.A.. As a result of successfully completing this milestone, Nabi is eligible to receive $8 million under the agreement governing Nabi's sale of PentaStaphTM (Pentavalent S. aureus Vaccine) and related assets to GSK.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Improved care for patients undergoing cancer surgery is the focus of a pioneering worldwide study.
Cellectis, the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.
For patients with serious, ongoing hip pain, sometimes surgery is their best bet for relief. Given the choice between minimally invasive hip surgery and total hip replacement, most patients would choose the less invasive procedure, often done on an outpatient basis.
Prostate cancer is the second leading cause of cancer-related death among American men. Yet population-wide screening programs have not reduced the number of deaths from the disease. By focusing screening programs on the men who are at greatest risk for aggressive disease or diagnosis at a young age, researchers think they could improve mortality rates and personalize the screening approach.
Nabi Biopharmaceuticals announced today that it has successfully completed the technology transfer of program know-how associated with the sale of the PentaStaphTM vaccine candidate to GlaxoSmithKline Biologicals S.A.. As a result of successfully completing this milestone, Nabi is eligible to receive $8 million under the agreement governing Nabi's sale of PentaStaphTM (Pentavalent S. aureus Vaccine) and related assets to GSK.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 11.61 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.51 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 62.7 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.08 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 21.07 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 93.4 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.71 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 52.08 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 4.49 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 30.61 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 26.91 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.06 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.21 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 58.12 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 68.4 | 82.93 |
News Archive
Improved care for patients undergoing cancer surgery is the focus of a pioneering worldwide study.
Cellectis, the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.
For patients with serious, ongoing hip pain, sometimes surgery is their best bet for relief. Given the choice between minimally invasive hip surgery and total hip replacement, most patients would choose the less invasive procedure, often done on an outpatient basis.
Prostate cancer is the second leading cause of cancer-related death among American men. Yet population-wide screening programs have not reduced the number of deaths from the disease. By focusing screening programs on the men who are at greatest risk for aggressive disease or diagnosis at a young age, researchers think they could improve mortality rates and personalize the screening approach.
Nabi Biopharmaceuticals announced today that it has successfully completed the technology transfer of program know-how associated with the sale of the PentaStaphTM vaccine candidate to GlaxoSmithKline Biologicals S.A.. As a result of successfully completing this milestone, Nabi is eligible to receive $8 million under the agreement governing Nabi's sale of PentaStaphTM (Pentavalent S. aureus Vaccine) and related assets to GSK.
› Verified 7 days ago
Greenwood Healthcare Center Location: 377 Westridge Blvd, Greenwood, Indiana 46142 Phone: (317) 888-4948 | |
Greenwood Health And Living Community Location: 937 Fry Rd, Greenwood, Indiana 46142 Phone: (317) 881-3535 | |
Aspen Trace Health & Living Community Location: 3154 South State Road 135, Greenwood, Indiana 46143 Phone: (317) 535-3344 |